WASHINGTON, April 04, 2023 (GLOBE NEWSWIRE) -- The Global Non Alcoholic Steatohepatitis (NASH) Market is valued at USD 1,569 Million in 2021 and is projected to reach a value of USD 21,879 Million by 2028 at a CAGR (Compound Annual Growth Rate) of 60.4% over the forecast period 2022-2028.
Market Overview
Non-alcoholic steatohepatitis (NASH) is a liver disease that is characterized by the accumulation of fat in the liver, inflammation, and damage to liver cells. NASH is a growing problem worldwide, and it is estimated that it affects up to 25% of adults in the United States.
The exact cause of NASH is unknown, but it is thought to be caused by a combination of factors, including obesity, diabetes, and high blood pressure. NASH can progress to fibrosis (scarring of the liver), cirrhosis (advanced scarring of the liver), and liver failure.
There is no cure for NASH, but there are treatments that can help to manage the condition. These treatments include lifestyle changes, such as losing weight, eating a healthy diet, and exercising regularly. Medications are also available to treat NASH, and there are a number of clinical trials underway to test new treatments.
The NASH market is expected to grow significantly in the coming years due to the increasing prevalence of the condition. The market is being driven by the development of new diagnostic tests and treatments for NASH.
Get Access to Free Sample Research Report with Latest Industry Insights @ https://www.vantagemarketresearch.com/non-alcoholic-ateatohepatitis-nash-market-1253/request-sample
Market Dynamics
- The increasing prevalence of NASH: NASH is a growing problem worldwide, and it is estimated that it affects up to 25% of adults in the United States. The prevalence of NASH is expected to increase in the coming years due to the rising rates of obesity, diabetes, and high blood pressure.
- The development of new diagnostic tests: There are a number of new diagnostic tests for NASH that are being developed. These tests will help to improve the diagnosis of NASH, which will lead to more people being treated for the condition.
- The development of new treatments: There are a number of new treatments for NASH that are being developed. These treatments will help to improve the management of NASH, which will lead to a better quality of life for people with the condition.
- The increasing awareness of NASH: There is a growing awareness of NASH among healthcare professionals and the general public. This increased awareness is leading to more people being diagnosed with NASH and seeking treatment.
Top Players in the Global Non-Alcoholic Steatohepatitis (NASH) Market
- Genfit
- Allergan plc (Tobira Therapeutics Inc.)
- Bristol-Myers Squibb Company
- Conatus Pharmaceuticals
- Galectin Therapeutics Inc.
Budget Limitation? Contact us for Special Discount and Pricing
Top Report Findings
- The global NASH market is expected to reach $21,879 Million by 2028, registering a CAGR of 60.4% from 2021 to 2028.
- The rising prevalence of obesity and diabetes is a major factor driving the growth of the NASH market.
- The development of new diagnostic tests and treatments for NASH is also contributing to the growth of the market.
- The North American region is expected to hold the largest share of the NASH market during the forecast period.
- The key players operating in the NASH market are Genfit, Allergan plc (Tobira Therapeutics, Inc.), Bristol-Myers Squibb Company, Conatus Pharmaceuticals, Galectin Therapeutics, Inc.
The NASH market is highly competitive, with a number of major companies developing and marketing treatments for the condition. The leading companies in the market are investing heavily in research and development to develop new and effective treatments for NASH.
The NASH market is expected to grow significantly in the coming years, as the prevalence of the condition continues to increase. The market is also expected to benefit from the development of new diagnostic tests and treatments for NASH.
Top Trends in Global Non-Alcoholic Steatohepatitis (NASH) Market
- The increasing prevalence of NASH: NASH is a liver disease that is characterized by the buildup of fat in the liver, inflammation, and damage to liver cells. It is a progressive condition that can lead to fibrosis, cirrhosis, and liver failure. NASH is a major public health problem, as it is estimated that over 25% of adults in the United States have the condition.
- The rising demand for effective treatments: There is no cure for NASH, but there are treatments that can help to manage the condition. These treatments include lifestyle changes, such as losing weight, eating a healthy diet, and exercising regularly. Medications are also available to treat NASH, and there are a number of clinical trials underway to test new treatments.
- The growing awareness about NASH: There is a growing awareness about NASH among healthcare professionals and the general public. This increased awareness is leading to more people being diagnosed with NASH and seeking treatment.
- The development of new diagnostic tests: There are a number of new diagnostic tests for NASH that are being developed. These tests will help to improve the diagnosis of NASH, which will lead to more people being treated for the condition.
- The development of new treatments: There are a number of new treatments for NASH that are being developed. These treatments will help to improve the management of NASH, which will lead to a better quality of life for people with the condition.
- The increasing focus on research and development: There is a growing focus on research and development for NASH. This is leading to the development of new diagnostic tests, treatments, and prevention strategies.
Buy this Premium Research Report with Discount | Immediate Delivery @ https://www.vantagemarketresearch.com/buy-now/non-alcoholic-ateatohepatitis-nash-market-1253/0
Regional Analysis
The global non-alcoholic steatohepatitis (NASH) market is segmented by region into North America, Europe, Asia Pacific, and the Rest of the World.
North America is expected to account for the largest share of the market, followed by Europe and Asia Pacific. The high prevalence of NASH in North America is attributed to the high rates of obesity, diabetes, and high blood pressure in the region. The increasing awareness about NASH and the availability of effective treatments are also driving the growth of the NASH market in North America.
Europe is expected to be the second-largest market for NASH, followed by Asia Pacific. The increasing prevalence of NASH in Europe is attributed to the aging population and the rising rates of obesity and diabetes in the region. The increasing awareness about NASH and the availability of effective treatments are also driving the growth of the NASH market in Europe.
Asia Pacific is expected to be the fastest-growing market for NASH, owing to the rising prevalence of obesity and diabetes in the region. The increasing awareness about NASH and the availability of effective treatments are also driving the growth of the NASH market in Asia Pacific.
The Rest of the World is expected to be a relatively small market for NASH, but it is expected to grow at a significant rate during the forecast period. The growth of the NASH market in the Rest of the World is attributed to the increasing prevalence of obesity and diabetes in the region. The increasing awareness about NASH and the availability of effective treatments are also driving the growth of the NASH market in the Rest of the World.
Browse market data Tables and Figures spread through 169 Pages and in-depth TOC on Non Alcoholic Steatohepatitis (NASH) Market Forecast Report (2022-2028).
Global Non Alcoholic Steatohepatitis (NASH) Market Segmentation
Drug Type
- Vitamin E & Pioglitazone
- Ocaliva
- Elafibranor
- Selonsertib
- Cencicriviroc
- Others
Sales Channel
- Hospital Pharmacy
- Online Provider
- Retail Pharmacy
Region
- North America
- Latin America
- Europe
- Asia Pacific
- Middle East & Africa
Read Full Report with TOC @ https://www.vantagemarketresearch.com/industry-report/non-alcoholic-ateatohepatitis-nash-market-1253
Scope of the Report:
Report Attributes | Details |
Market Size in 2021 | USD 1,569 Million |
Revenue Forecast by 2028 | USD 21,879 Million |
CAGR | 60.4% from 2021 to 2028 |
Base Year | 2022 |
Forecast Year | 2023 to 2028 |
Key Players | Genfit, Allergan plc (Tobira Therapeutics, Inc.), Bristol-Myers Squibb Company, Conatus Pharmaceuticals, Galectin Therapeutics, Inc. |
Customization Request | If our report does not include the information you are searching for, you may contact us to have a report tailored to your specific business needs https://www.vantagemarketresearch.com/non-alcoholic-ateatohepatitis-nash-market-1253/request-sample |
Key Questions Answered in the Non Alcoholic Steatohepatitis (NASH) Market Report are:
- What is the global NASH market size and forecast from 2022 to 2028?
- What are the key factors driving the growth of the NASH market?
- What are the key trends observed in the NASH market?
- What are the key challenges faced by the NASH market?
- Who are the key players operating in the NASH market?
- What are the strategies adopted by the key players to sustain in the NASH market?
- What are the key opportunities and threats faced by the NASH market?
- What are the key findings of the NASH market report?
Browse More Reports from Vantage Library:
- Non-UV Dicing Tapes Market Size USD 2,104.9 Million by 2028: https://www.vantagemarketresearch.com/industry-report/non-uv-dicing-tapes-market-1742
- Non Invasive Fat Reduction Market Size USD 1903.2 Million by 2028: https://www.vantagemarketresearch.com/industry-report/non-invasive-fat-reduction-market-1319
- Medical Non-Woven Disposables Market Size USD 18769.1 Million by 2028: https://www.vantagemarketresearch.com/industry-report/medical-non-woven-disposables-market-1316
- Non-photo Personalized Gifts Market: https://www.vantagemarketresearch.com/industry-report/non-photo-personalized-gifts-market-0534
- Non-Destructive Testing Equipment Market: https://www.vantagemarketresearch.com/industry-report/non-destructive-testing-equipment-market-0294
- Non-Destructive Testing (Ndt) Equipment Market: https://www.vantagemarketresearch.com/industry-report/non-destructive-testing-ndt-equipment-market-0290
- Nonprofit CRM Software Market: https://www.vantagemarketresearch.com/industry-report/nonprofit-crm-software-market-0213
About Vantage Market Research:
We, at Vantage Market Research, provide quantified B2B high quality research on more than 20,000 emerging markets, in turn, helping our clients map out constellation of opportunities for their businesses. We, as a competitive intelligence market research and consulting firm provide end to end solutions to our client enterprises to meet their crucial business objectives. Our clientele base spans across 70% of Global Fortune 500 companies.
Follow Us on: LinkedIn | Twitter | Facebook | YouTube
Contact us
Eric Kunz
6218 Georgia Avenue NW Ste 1 - 564
Washington DC 20011-5125
United States Tel: +1 202 380 9727
Email: sales@vantagemarketresearch.com
Website:
https://www.vantagemarketresearch.com/
Latest Vantage Market Research Press Releases
Latest Vantage Market Research Blog
Vantage Market Research All Reports
Blog: